Log in

IntelliPharmaCeutics Intl News Headlines (OTCMKTS:IPCIF)

$0.18
-0.02 (-10.23 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$0.17
Now: $0.18
$0.21
50-Day Range
$0.15
MA: $0.48
$0.92
52-Week Range
$0.09
Now: $0.18
$0.95
Volume587,220 shs
Average Volume1.01 million shs
Market Capitalization$3.88 million
P/E RatioN/A
Dividend YieldN/A
Beta2.74

Headlines

IntelliPharmaCeutics Intl (OTCMKTS IPCIF) News Headlines

Source:
DateHeadline
Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Aximris XR(TM) (Oxycodone Hydrochloride extended release) an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe PainIntellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Aximris XR(TM) (Oxycodone Hydrochloride extended release) an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
finance.yahoo.com - January 16 at 12:50 PM
FDA Ad Com thumbs down on Intellipharmaceutics oxycodone ERFDA Ad Com thumbs down on Intellipharmaceutics' oxycodone ER
seekingalpha.com - January 16 at 12:02 AM
Intellipharmaceutics down 13% ahead of Ad Com meeting on oxycodone ERIntellipharmaceutics down 13% ahead of Ad Com meeting on oxycodone ER
seekingalpha.com - January 14 at 5:02 PM
Intellipharmaceutics Announces FDA Advisory Committee Meeting for Aximris XR(TM) (Oxycodone Hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe PainIntellipharmaceutics Announces FDA Advisory Committee Meeting for Aximris XR(TM) (Oxycodone Hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
finance.yahoo.com - December 5 at 1:34 PM
Intellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc. for Venlafaxine ERIntellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc. for Venlafaxine ER
finance.yahoo.com - November 25 at 8:07 PM
Intellipharmaceutics Closes USD$250,000 Convertible Debenture Financing with Drs. Isa and Amina OdidiIntellipharmaceutics Closes USD$250,000 Convertible Debenture Financing with Drs. Isa and Amina Odidi
finance.yahoo.com - November 18 at 5:55 PM
Intellipharmaceutics Update on its Oxycodone ER New Drug ApplicationIntellipharmaceutics Update on its Oxycodone ER New Drug Application
finance.yahoo.com - October 24 at 6:13 PM
Intellipharmaceutics Announces Third Quarter 2019 ResultsIntellipharmaceutics Announces Third Quarter 2019 Results
finance.yahoo.com - October 11 at 5:42 PM
Intellipharmaceutics International Inc.: Intellipharmaceutics Announces an Update in the Purdue LitigationIntellipharmaceutics International Inc.: Intellipharmaceutics Announces an Update in the Purdue Litigation
www.finanznachrichten.de - October 6 at 1:24 PM
Intellipharmaceutics Signs a Second Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc.Intellipharmaceutics Signs a Second Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc.
finance.yahoo.com - September 24 at 4:49 PM
Intellipharmaceutics International Inc. Announces Update on its Oxycodone ER New Drug ApplicationIntellipharmaceutics International Inc. Announces Update on its Oxycodone ER New Drug Application
finance.yahoo.com - July 24 at 5:38 PM
Intellipharmaceutics International Inc.: Intellipharmaceutics Announces Second Quarter 2019 ResultsIntellipharmaceutics International Inc.: Intellipharmaceutics Announces Second Quarter 2019 Results
www.finanznachrichten.de - July 11 at 10:04 AM
Intellipharmaceutics International Inc. Announces $10,000,000 Equity Financing CommitmentIntellipharmaceutics International Inc. Announces $10,000,000 Equity Financing Commitment
finance.yahoo.com - July 9 at 11:02 AM
Intellipharmaceutics International Inc.: Intellipharmaceutics to present at the 9th Annual LD Micro InvitationalIntellipharmaceutics International Inc.: Intellipharmaceutics to present at the 9th Annual LD Micro Invitational
www.finanznachrichten.de - May 29 at 10:48 AM
U.S. FDA Acknowledges Receipt of Intellipharmaceutics Resubmission of Oxycodone ER New Drug Application, Deems it a Complete Response, and Designates August 28, 2019 as Goal Date for ReviewU.S. FDA Acknowledges Receipt of Intellipharmaceutics' Resubmission of Oxycodone ER New Drug Application, Deems it a Complete Response, and Designates August 28, 2019 as Goal Date for Review
finance.yahoo.com - March 29 at 12:18 PM
Intellipharmaceutics Receives Nasdaq Listing Determination; To Begin Trading on the OTC Markets SystemIntellipharmaceutics Receives Nasdaq Listing Determination; To Begin Trading on the OTC Markets System
finance.yahoo.com - March 20 at 11:20 AM
Four Marijuana Stocks Green and Ready for the PickingFour Marijuana Stocks Green and Ready for the Picking
finance.yahoo.com - March 4 at 4:12 PM
Intellipharmaceutics International Inc.: Intellipharmaceutics Announces Resubmission of New Drug Application to the U.S. FDA for its Oxycodone ERIntellipharmaceutics International Inc.: Intellipharmaceutics Announces Resubmission of New Drug Application to the U.S. FDA for its Oxycodone ER
www.finanznachrichten.de - March 4 at 8:11 AM
Intellipharmaceutics Receives Extension from Nasdaq Hearings PanelIntellipharmaceutics Receives Extension from Nasdaq Hearings Panel
finance.yahoo.com - January 29 at 11:19 AM
Intellipharmaceutics Announces Research and Development Program for a Pipeline of Pharmaceutical Cannabidiol Based ProductsIntellipharmaceutics Announces Research and Development Program for a Pipeline of Pharmaceutical Cannabidiol Based Products
finance.yahoo.com - January 7 at 10:12 AM
This page was last updated on 1/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel